1. Home
  2. CTO vs OMER Comparison

CTO vs OMER Comparison

Compare CTO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CTO Realty Growth Inc.

CTO

CTO Realty Growth Inc.

HOLD

Current Price

$22.00

Market Cap

695.9M

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$9.81

Market Cap

772.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTO
OMER
Founded
1902
1994
Country
United States
United States
Employees
42
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
695.9M
772.8M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
CTO
OMER
Price
$22.00
$9.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
5
Target Price
$22.50
$32.50
AVG Volume (30 Days)
374.8K
1.8M
Earning Date
04-28-2026
05-14-2026
Dividend Yield
7.44%
N/A
EPS Growth
N/A
98.15
EPS
N/A
0.62
Revenue
N/A
$29,868,000.00
Revenue This Year
$7.63
N/A
Revenue Next Year
$2.76
$233.22
P/E Ratio
N/A
$16.58
Revenue Growth
N/A
N/A
52 Week Low
$15.07
$3.44
52 Week High
$22.66
$17.65

Technical Indicators

Market Signals
Indicator
CTO
OMER
Relative Strength Index (RSI) 57.83 47.35
Support Level $21.11 $9.40
Resistance Level $22.66 $10.77
Average True Range (ATR) 0.40 0.55
MACD -0.00 0.05
Stochastic Oscillator 60.84 44.94

Price Performance

Historical Comparison
CTO
OMER

About CTO CTO Realty Growth Inc.

CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: